期刊文献+

一种新型广谱流感病毒亚单位疫苗的表达与纯化 被引量:2

Expression and Purification of a Novel Influenza Virus Subunit Vaccine
在线阅读 下载PDF
导出
摘要 通过引物设计,利用重叠延伸PCR(OE-PCR)和搭桥PCR方法扩增得到A型流感病毒M2蛋白缺失跨膜区基因以及HA多表位基因,分别克隆测序后以pET28a+为表达载体构建重组质粒pET28a+-M2d-HA。将重组质粒转化大肠杆菌BL21(DE3),筛选获得了高效表达流感病毒缺失跨膜区M2蛋白和HA多表位蛋白片段重组融合蛋白的工程菌,表达的重组蛋白约占菌体总蛋白的45%左右。表达的蛋白以包涵体形式存在,包涵体经亲和层析和阴离子交换层析纯化后复性,得到纯度在90%以上的目的蛋白。Westernblot结果显示纯化的重组蛋白具有较好的抗原性和特异性。为进一步研究广谱型流感病毒亚单位疫苗奠定了基础。 The influenza A virus matrix protein2 gene(M2) which deleted transmembrane region was amplified by overlap extending PCR, and the multi-epitope gene of hemagglutinin (HA) was PCR amplified with seven continuous synthesized segments by designing primer. The two gene segments were separately cloned into pMD18-T vector to sequence analysis and prokarytic expression vector pET28a + to construct the recombinant plasmid pET28a + -M2d-HA. The recombinant plasmid was transformed into E. coli BL21 (DE3), and the high expression strain was obtained by screening monoelones. The recombinant protein existed as inclusion bodies, which accounted about 45% of the total cellular protein. The inclusion bodies were washed with 1% Triton X-100 solution twice, and dissolved in 8 moL/L urea solution. The solution protein was purified by Ni2^+ affinity chromatography, and refolded by dilution renaturation, then purified by Q Sepharose FIr cation exchange column. The purity of the protein was over 90% by HPLC analysis. The result of Western blot showed it has good antigenicity and specificity. These results strongly supported for the further study of the broad-spectrum influenza virus subunit vaccine.
出处 《中国生物工程杂志》 CAS CSCD 北大核心 2007年第5期90-95,共6页 China Biotechnology
基金 云南省自然科学基金资助项目(2005C0062M)
关键词 流感病毒 亚单位疫苗 多表位 表达纯化 抗原性 Influenza virus Subunit vaccine Multiepitope Expression and purification Antigenicity
  • 相关文献

参考文献13

  • 1Frace A M,Klimov A T,Rowe T,et al.Modified M2 proteins produce heterotypic immunity against influenza A virus.Vaccine,1999,17:2237~2244
  • 2Hua Li,Ding J,Chen Y H.Recombinant protein comprising muli-neutralizing epitopes induced high titer of antibodies against Influecza A Virus.Immunobiol,2003,207:305~313
  • 3Raphael Levi,Arnon R.Synthetic recombination influenza vaccine induces efficient long-term immunity and cross-strain protection.Vaccine,1996,14(1):85~92
  • 4Brumeanu T D,Casares S,Bot A,et al.Immunogenicity of a contiguous T-B synthetic epitope of the A/PR/8/34 influenza virus.J Virol,1997,71:5473~5480
  • 5Rajnavolgyi E,Horvath A,Gogolak P,et al.Characterizing immunodominant and protective influenza hemagglutinin epitopes by functional activity and relative binding to major histocompatibility complex class Ⅱ sites.Eur J Immunol,1997,27(12):3105~3114
  • 6McEwen J,Levi R,Horwitz R J,et al.Synthetic recombinant vaccine expressing influenza haemagglutinin epitope in Salmonella flagellin leads to partial protection in mice.Vaccine,1992,10(6):405~411
  • 7Simeckova-Rosenberg J,Yun Z,Wyde P R,et al.Protection of mice against lethal viral infection by synthetic peptides corresponding to B-and T-cell recognition sites of influenza A hemagglutinin.Vaccine,1995,13(10):927~932
  • 8Naruse H,Ogasawara K,Takami K,et al.Analysis of epitopic residues introduced into the hybrid peptide vaccines prepared according to the cassette theory.Vaccine,1994,12(9):776~782
  • 9Falk K,Rotzschke O,Strominger J L.Antigen-specific elimination of T cells induced by oligomerized hemagglutinin (HA) 306-318.Eur J Immunol,2000,30(10):3012~3020
  • 10Tamura S,Tanimoto T,Kurata T.Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines.J Infect,2005,58:195~207

二级参考文献55

  • 1CLARK E D B.Protein refolding for industrial processes[J]. Current Opinion in Biotechnology,2001,12:202-207.
  • 2KOHNO T,CARMICHAEL D F,SOMMER A,et al.Refolding of recombinant proteins[J]. Methods Enzymol,1990,185:187-195.
  • 3VAN KIMMENADE A,BOND M W,SCHUMACHER J H,et al.Expression,renaturation and purification of recombinant human Interleukin 4 from Escherichia coli[J].Eur J Biochem,1988,173:109-114.
  • 4CLARK E D B.Refolding of recombinant proteins[J]. Curr Opin Biotechnol,1998,9(2):157-163.
  • 5MAEDA Y,UEDA T,IMOTO T.Effective renaturation of denatured and reduced immunoglobulin G in vitro without assistance of chaperone[J].Protein Eng,1996,9(1):95-100.
  • 6HWANG H S,CHUNG H S.Preparation of active recombinant cathepsin K expressed in bacteria as inclusion body[J]. Protein Expr Purif,2002,25(3):541-546.
  • 7WEST S M,CHAUDHUI J B,HOWELL J A.Improved protein refolding using hollow-fibre membrane dialysis[J]. Biotechnol Bioeng,1998,57(5):590-599.
  • 8FAHEY E M,CHAUDHURI J B,BINDING P.Refolding and purification of urokinase plaminogen activator fragment by chromatography[J]. J Chromatogr B Biomed Sci Appl,2000,737(1-2):225-235.
  • 9HAN B,HALL F L,NIMNI M E.Refolding of a recombinant collagon-targeted TGF-beta2 fusion protein expressed in Escherichia coli[J].Protein Expr Purif,1997,11 (2):169-178.
  • 10SMITH V R,WALKER J E.Purification and folding of recombinant bovine oxoglutarate/malate carrier by immobilized metal-ion affinity chromatography[J]. Protein Expr Purif,2003,29(2):209-216.

共引文献36

同被引文献22

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部